Randomized Double Blind Placebo-controlled Trial of the Efficacy of an Anti-TNF Alpha Agent (Adalimumab, Humira) in Patients With Incapacitating Hand Osteoarthritis Refractory to Usual Treatment

Trial Profile

Randomized Double Blind Placebo-controlled Trial of the Efficacy of an Anti-TNF Alpha Agent (Adalimumab, Humira) in Patients With Incapacitating Hand Osteoarthritis Refractory to Usual Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2015

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Acronyms DORA
  • Most Recent Events

    • 09 May 2014 Results published in the Annals of the Rheumatic Diseases.
    • 15 Jun 2013 Results presented at the 14th Annual Congress of the European League Against Rheumatism.
    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top